Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3-Angle Plc

12 May 2008 13:20

RNS Number : 2093U
Kaupthing Bank hf
12 May 2008
ย 
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
ย 
ย 
1. KEY INFORMATION
ย 
Name of person dealing (Note 1)
Kaupthing Bank hf
Company dealt in
Angle Plc
Class of relevant security to which the dealings being disclosed relate(Note 2)
Ordinary Shares
Date of dealing
09 May 2008
ย 
ย 
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
ย 
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
ย 
ย 
ย 
Long
Short
ย 
ย 
Number (%)
Number (%)
(1) Relevant securities
ย 
ย 
9,418 (0.03%)
(2) Derivatives (other than options)
ย 
1,017,125 (3.75 %)
ย 
1,017,125 (3.75 %)
ย 
(3) Options and agreements to purchase/sell
ย 
ย 
ย 
Total
ย 
1,017,707 (3.75 %)
ย 
1,026,543 (3.78 %)
ย 
ย 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
ย 
Class of relevant security:
ย 
Long
Short
ย 
ย 
Number (%)
Number (%)
(1) Relevant securities
ย 
ย 
ย 
(2) Derivatives (other than options)
ย 
ย 
ย 
(3) Options and agreements to purchase/sell
ย 
ย 
ย 
Total
ย 
ย 
ย 
ย 
(c) Rights to subscribe (Note 3)
ย 
Class of relevant security:
ย 
Details
ย 
ย 
ย 
ย 
ย 
3. DEALINGS (Note 4)
ย 
(a) Purchases and salesย 
ย 
Purchase/sale
ย 
Number of securities
Price per unit (Note 5)
Sell
10,000
39.50p
ย 
ย 
ย 
ย (b) Derivatives transactions (other than options)
ย 
Product name,
e.g. CFD
Long/short (Note 6)
Number of securities (Note 7)
Price per unit (Note 5)
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
ย 
Product name,
e.g. call option
ย 
Writing, selling,ย purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise
price
Type, e.g. American, European etc.
Expiry
date
Option money
paid/received per unit (Note 5)
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
ย 
(ii) Exercising
ย 
Product name, e.g. call option
Number of securities
Exercise price per unit (Note 5)
ย 
ย 
ย 
ย 
ย 
ย 
(d) Other dealings (including new securities) (Note 4)
ย 
Nature of transaction (Note 8)
ย 
Details
Price per unit (if applicable)(Note 5)
ย 
ย 
ย 
ย 
ย 
ย 
4. OTHER INFORMATION
ย 
Agreements, arrangements or understandings relating to options or derivatives
ย 
ย 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.ย If none, this should be stated.ย 
No voting rights on CFD holdings
ย 
ย 
ย 
Is a Supplemental Form 8 attached? (Note 9) NO
ย 
ย 
Date of disclosure
12 May 2008
Contact name
Richard Easton
Telephone number
0203 205 6620
If a connected EFM, name of offeree/offeror with which connected
ย 
If a connected EFM, state nature of connection (Note 10)
ย 
ย 
ย 
Notes
ย 
The Notes on Form 8.3 can be viewed on the Takeover Panelโ€™s website at www.thetakeoverpanel.org.uk
ย 
ย 
This information is provided by RNS
The company news service from the London Stock Exchange
ย 
END
ย 
ย 
RETXLLFFVEBFBBD
Date   Source Headline
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting
2nd Jul 20187:00 amRNSNotice of Preliminary Results
25th Jun 20186:20 pmRNSResults of Fundraising
25th Jun 20182:58 pmRNSClose of Accelerated Bookbuild
25th Jun 20187:50 amRNSProposed Placing of New Ordinary Shares
4th Jun 20187:00 amRNSENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14th May 20187:00 amRNSLeading cancer surgeon appointed
3rd May 20187:00 amRNSAngle & QIAGEN Poster
19th Apr 20187:00 amRNSParsortix in multiple presentations at AACR
19th Apr 20187:00 amRNSBreakthrough Research with Parsortix
5th Apr 20187:00 amRNSFirst patient enrolled in FDA study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.